This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (33)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Michael E. Smith, MD; Robert Gunther, PhD; Conrad Zaiss; Robert H. Demling, MD

Arch Surg. 1982;117(2):175-180.

Abstract
• The use of prostaglandins is currently undergoing clinical trials in respiratory failure accompanying sepsis. The effect of prostaglandin E₁ (PGE₁) and prostacyclin (PGI₂) infusion on endotoxin-induced lung injury, with attention to interstitial fluid flux (Q_L), pulmonary vascular pressure (P[unk]), leukocytes, platelets, and release of the lysosomal enzyme β-glucuronidase, was investigated. A chronic lung lymph fistula model in sheep was used. Seven sheep alternately received Escherichia coli endotoxin and endotoxin plus PGE₁ at a dosage of 1 µg/kg/min. Six sheep received PGI₂ (0.2 µg/kg/min) instead of PGE₁. Both PGE₁ and PGI₂ decreased the pulmonary hypertension and the interstitial edema produced by endotoxin primarily through their vasodilatory properties. Prostacyclin seemed to have an additional membrane-stabilizing effect. A rebound increase in Q_L, P[unk], and platelets occurred when PGE₁ or PGI₂ infusion was discontinued.

(Arch Surg 1982;117:175-180)

Author Affiliations
From the Department of Surgery, University of California at Davis, Sacramento.

Footnotes
Accepted for publication Aug 21, 1981.

Read at the first annual meeting of the Surgical Infection Society, Chicago, April 25, 1981.

Reprints not available.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?